Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 48, Issue 3, Pages 333-339
Publisher
Wiley
Online
2018-06-20
DOI
10.1111/apt.14834
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience
- (2018) P. Wils et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
- (2018) A. Barré et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease
- (2017) Parakkal Deepak et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Therapeutic Drug Monitoring During Induction of Anti–Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
- (2017) Konstantinos Papamichael et al. INFLAMMATORY BOWEL DISEASES
- Positioning Ustekinumab in Crohn’s Disease: From Clinical Evidence to Clinical Practice
- (2017) Silvio Danese et al. Journal of Crohns & Colitis
- Crohn Disease: Epidemiology, Diagnosis, and Management
- (2017) Joseph D. Feuerstein et al. MAYO CLINIC PROCEEDINGS
- Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey
- (2017) Christopher Ma et al. BMJ Open
- An estimate of the cost of administering intravenous biological agents in Spanish day hospitals
- (2017) Joan Miquel Nolla et al. Therapeutics and Clinical Risk Management
- Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease
- (2016) David J Gracie et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC
- (2016) Jean-Frédéric Colombel et al. GUT
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Relationship Among Perceived Stress, Symptoms and Inflammation in Persons With Inflammatory Bowel Disease
- (2015) Laura E Targownik et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting
- (2015) S.P. Menting et al. BRITISH JOURNAL OF DERMATOLOGY
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD
- (2015) Konstantinos Papamichael et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
- (2014) Y. Mazor et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience
- (2014) U. Kopylov et al. Journal of Crohns & Colitis
- Top-Down or Step-Up Treatment in Crohn's Disease?
- (2013) Gerhard Rogler DIGESTIVE DISEASES
- Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease
- (2013) Yi-Lin Chiu et al. INFLAMMATORY BOWEL DISEASES
- The Short Health Scale: A valid and reliable measure of health related quality of life in English speaking inflammatory bowel disease patients
- (2012) Edel McDermott et al. Journal of Crohns & Colitis
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change
- (2011) I. Ordas et al. GUT
- The Natural History of Adult Crohn's Disease in Population-Based Cohorts
- (2009) Laurent Peyrin-Biroulet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started